Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
If he pulls it off, he will make more than all of his peers combined.
Overall deal value declined last year.
The biotech giant can now speed up the drug review process.
These tech and pharma companies could cash in on "repatriation."
It's to protect the company's best-selling drug.